Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

CSF Tyrosine

Body Fluids

Tyr (CSF)Tyrosine, CSF

Review status

Currently under review

Pending specialist review and validation.

What it shows

This test measures the amount of tyrosine, an amino acid, in your cerebrospinal fluid (CSF). CSF surrounds your brain and spinal cord, so its composition can reflect what is happening in the central nervous system more directly than a blood test.

Doctors may order CSF tyrosine as part of a broader amino acid profile when evaluating neurologic symptoms or suspected metabolic conditions. The sample is collected during a lumbar puncture and handled under specific laboratory conditions to preserve amino acids for accurate analysis.

Why it matters

Tyrosine levels in CSF can provide clues about how your body processes certain amino acids and how well these substances move between the blood and the brain. Abnormal levels can be seen with inherited metabolic conditions that affect tyrosine pathways, with disorders that change amino acid transport into the brain, or as an effect of specific treatments.

Your clinician might order this test if you have unexplained seizures, developmental concerns, movement disorders, or other neurologic changes, especially when a metabolic cause is being considered. Results are interpreted alongside plasma amino acids, urine studies, imaging, and your clinical history to guide diagnosis and treatment.

Understanding your results

If your CSF tyrosine is higher than expected, your clinician will consider medications, diet, and underlying liver or metabolic conditions, and will also check whether the sample was contaminated with blood. If it is lower than expected, transport problems across the blood brain barrier, nutritional issues, or other metabolic disorders may be considered.

Most of the time, this test is one piece of a larger evaluation. Your care team may repeat the test if the sample was difficult to collect, review your current medications and supplements, and order additional studies such as a full CSF amino acid profile, plasma amino acids, or genetic testing. Discuss any questions with your clinician so you understand what the results mean for you and what steps come next.

Reference ranges

520 umol/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact CSF Tyrosine

  • Blood contamination during lumbar puncture

    Red blood cells or serum leaking into the CSF sample can artificially raise amino acid measurements, including tyrosine. If a traumatic tap is suspected, your clinician may interpret results with caution or repeat testing.

  • Specimen handling and storage

    Amino acids are sensitive to delays and temperature. Prompt processing and freezing help preserve integrity. Improper handling can lead to misleading increases or decreases in measured tyrosine.

  • Medications and supplements

    Therapies that alter tyrosine metabolism or transport, such as nitisinone, large neutral amino acid formulations, levodopa, or tyrosine supplements, can affect CSF tyrosine and should be reviewed with the lab.

  • Diet and catabolic stress

    High protein intake, total parenteral nutrition, illness, or fasting can shift amino acid pools. While CSF is less immediately affected than blood, systemic changes can still influence CSF tyrosine over time.

  • Age and neurological conditions

    Developmental stage, neuroinflammation, or elevated CSF protein can alter amino acid patterns. Interpreting tyrosine alongside other CSF markers and clinical context improves accuracy.

2026

References

  1. McGill University Health Centre. (2015, February 04). CSF Tyrosine (Task CD 693415). Laboratory reference ranges.
  2. de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Chakrapani, A., & Habib Chellak, R. (2013). Recommendations for the management of tyrosinaemia type 1. Orphanet Journal of Rare Diseases, 8, 8.